Literature DB >> 20484708

Prevalence of methylphenidate prescription among school-aged children in a Swiss population: increase in the number of prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in patient demographics.

Cédric Gumy1, Thérèse Huissoud, Françoise Dubois-Arber.   

Abstract

OBJECTIVE: Methylphenidate is prescribed for children and adolescents to treat ADHD. As in many Western countries, the increase in methylphenidate consumption is a public concern in Switzerland. The article discusses the authors' assessment of prescription prevalence in 2002 and 2005 for school-aged children in the canton of Vaud.
METHOD: Pharmacy prescription information is available from the regional public health authority. Descriptive analyses are conducted on an anonymized database of the years 2002 and 2005. Data for each year are compared to assess trends in methylphenidate prescription prevalence.
RESULTS: The findings show an increase from 0.74% to 1.02% in the number of prescriptions for 5- to 14-year-old children, particularly in prescriptions for girls. Data also show important geographical differences in prescription.
CONCLUSION: The prevalence of methylphenidate prescription is lower in Switzerland than other Western countries, particularly the United States. However, some aspects of prevalence are similar, including the increase per year, demographics, and geographic characteristics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484708     DOI: 10.1177/1087054709356386

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  5 in total

Review 1.  Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.

Authors:  Christopher Steer; Jan Froelich; César A Soutullo; Mats Johnson; Monica Shaw
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 6.497

2.  Prescription, dispensation and marketing patterns of methylphenidate.

Authors:  Edson Perini; Daniela Rezende Garcia Junqueira; Lorena Gomes Cunha Lana; Tatiana Chama Borges Luz
Journal:  Rev Saude Publica       Date:  2014-12       Impact factor: 2.106

3.  Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland.

Authors:  Stéphane Deline; Stéphanie Baggio; Joseph Studer; Alexandra A N'Goran; Marc Dupuis; Yves Henchoz; Meichun Mohler-Kuo; Jean-Bernard Daeppen; Gerhard Gmel
Journal:  Int J Environ Res Public Health       Date:  2014-03-12       Impact factor: 3.390

4.  Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.

Authors:  S K Inglis; S Carucci; P Garas; A Häge; T Banaschewski; J K Buitelaar; R W Dittmann; B Falissard; C Hollis; H Kovshoff; E Liddle; S McCarthy; P Nagy; A Neubert; E Rosenthal; E Sonuga-Barke; I Wong; A Zuddas; D C Coghill
Journal:  BMJ Open       Date:  2016-04-26       Impact factor: 2.692

5.  Switzerland's Narcotics Regulation Jungle: Off-Label Use, Counterfoil Prescriptions, and Opioid Agonist Therapy in the French-Speaking Cantons.

Authors:  Caroline Schmitt-Koopmann; Carole-Anne Baud; Valérie Junod; Olivier Simon
Journal:  Int J Environ Res Public Health       Date:  2021-12-14       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.